Preoperative systemic immune-inflammation index predicts prognosis of patients with non-metastatic renal cell carcinoma: a propensity score-matched analysis

Xu Hu†, Yan-Xiang Shao†, Zhi-Qiang Yang†, Wei-Chao Dou†, San-Chao Xiong† and Xiang Li‡

Abstract

Background: A novel systemic immune-inflammation index (SII), based on the neutrophils, lymphocytes and platelet counts, is associated with the prognosis of several cancers. The present study evaluates the prognostic significance of SII in non-metastatic renal cell carcinoma (RCC).

Method: The present study retrospectively reviewed the medical record of patients with non-metastatic RCC who underwent nephrectomy between 2010 and 2013. Receiver operating characteristic (ROC) curve analysis was performed to identify the optimal cut-off value. In addition, the propensity score matching (PSM) was performed with a matching ratio of 1:1. Univariate and multivariate Cox proportional hazards models were used to identify the prognostic factors. The results were reported by hazard ratio (HR) with 95% confidence interval (95% CI).

Results: A total of 646 patients were included in the final analysis. High SII group (> 529) was significantly associated with older age (P = 0.014), larger tumor (P < 0.001), higher pathological T stage (P < 0.001), higher tumor grade (P < 0.001) and more tumor necrosis (P < 0.001). Multivariate Cox regression analysis demonstrated that the higher preoperative SII was significantly associated with worse overall survival (OS) (HR = 2.26; 95% CI 1.44–3.54; P < 0.001) and cancer-specific survival (CSS) (HR = 2.17; 95% CI 1.33–3.55; P = 0.002). After PSM, elevated preoperative SII was an independent predictor of poor OS (HR = 1.78; 95% CI 1.1–2.87; P = 0.018) and CSS (HR = 1.8; 95% CI 1.07–3.03; P = 0.027).

Conclusion: In conclusion, preoperative SII is associated with adverse factors for RCC. Furthermore, higher preoperative SII is an independent predictor of poor OS and CSS in surgically treated patients with non-metastatic RCC. More prospective and large scale studies are warranted to validate our findings.

Keywords: Systemic immune-inflammation index, Renal cell carcinoma, Non-metastatic, Prognosis

Background

Renal cell carcinoma (RCC) is one of the most common urological cancers and represents an increased global burden on human healthcare [1]. RCC accounts for approximately 2–3% of all malignancies, with an estimated 403,262 new cases and 175,098 new deaths worldwide in 2018 [2]. Surgical resection is the curative treatment for localized RCC [3]. However, reportedly, about 20–30% of patients will develop recurrence [4,}

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
of patients would be of great value to patients’ risk stratification, treatment selection, and long-term outcomes. Therefore, identifying the prognostic factors of patients would be of great value to patients’ risk stratification, treatment selection, and long-term outcomes.

TNM stage, tumor grade, and histology are commonly used prognostic factors, however, these factors would lack information about patient-related factors. Increasing evidence suggested that host inflammation response plays an important role in cancer development and progression [8, 9]. The complement system also plays an important role in the innate immune system. The complement system could recognize invading pathogens and eliminates them by several effector mechanisms that may also cause systemic inflammatory response, as well as using direct lytic destruction [10]. Besides, complement could be leveraged by neoplasms to promote tumorigenic microenvironments and antibody-dependent complement activity is associated with antitumor efficacy [11]. Previous reports have shown that circulating immune-inflammatory cells, such as lymphocytes, neutrophils, and platelet, could contribute to promoting cancer cell proliferation and invasion [8, 9, 12, 13]. Several studies have evaluated these circulating cells and found that they are associated with the prognosis of malignancies [13, 14].

A novel systemic immune-inflammation index (SII), based on the neutrophils, lymphocytes and platelet counts, has been found to be associated with the prognosis of several cancers, such as gastric cancer, hepatocellular carcinoma, bladder cancer as well as RCC [15–18]. However, the prognostic value of SII in non-metastatic RCC is not well explored. Hence, the present study was performed to evaluate the prognostic significance of preoperative SII in non-metastatic RCC patients who underwent nephrectomy.

The following clinicopathological characteristics were retracted from medical records: age, gender, hypertension, diabetes mellitus, tumor laterality, surgical approach and type, tumor stage, grade, neutrophils, lymphocytes, and platelet counts. All laboratory tests were performed within 1 week before surgery. SII was calculated based on the following formula: platelet × neutrophil/lymphocyte. In addition, the X-ray or computed tomography (CT) scan of the chest and CT or magnetic resonance imaging (MRI) scan of the abdomen should have been performed for patients to identify the preoperative stage. Lymph node dissection was conducted in patients with enlarged nodes on preoperative imaging or palpable nodes during surgery. Tumor size was recorded as the longest tumor diameter based on the pathological report. The pathological stage was classified based on the 8th edition of the tumor-node-metastasis (TNM) classification [19]. The pathological evaluation was made according to the 2016 WHO classification [20].

Follow-up data
All patients were followed up regularly, every 3 months within 2 years after surgery, every 6 months for the next 3 years, and then once a year. Patients should undergo a medical history, physical examination, laboratory test, X-ray or CT of the chest, ultrasound or CT or MRI of the abdomen. The clinical outcomes include overall survival (OS) and cancer-specific survival (CSS). OS is defined as the interval time between the day of surgery and the last follow-up or all-cause death. CSS is measured from the day of surgery and last follow-up or cancer-related death.

Statistical analysis
Continuous variables are presented as mean ± standard deviation (SD) or median (interquartile range, IQR). Categorized variables are described as frequency (percentage). Chi square test and Student’ t test were used to compare the categorized and continuous variables, respectively. Receiver operating characteristic (ROC) curve analysis was performed to identify the sensitivity and specificity of the prognostic factor. The optimal cut-off value of the prognostic factor was chosen based on the Youden Index. Kaplan–Meier survival curve and the log-rank test were carried out to compare the survival outcomes between groups. Univariate and multivariate Cox proportional hazards models were used to identify the prognostic factors of OS and CSS. The results were reported by hazard ratio (HR) with 95% confidence interval (95% CI).

In addition, the propensity score matching (PSM) was performed using the nearest neighbor method with 0.02 calibration adjusting for preoperative characteristics. The matching ratio is 1:1, and SII (low vs high)
is the dependent variable. The standardized difference was calculated to evaluate the covariate balance, with a value < 0.10 regarded as balanced [21]. A two-tailed P value < 0.05 was regarded as statistically significant. All statistical analyses were performed by R software version 3.6.2 (http://www.r-project.org/) and IBM SPSS Statistics version 23.0 (IBM Corp, Armonk, NY).

**Results**

**Clinical characteristics of patients**

The clinical characteristics of the included patients were summarized in Table 1. The mean age of the patients was 54.77 years (SD ± 12.61). The final cohort included 394 men (60.99%) and 252 women (39.01%) with a mean tumor size of 4.97 cm (SD ± 2.53). More than half of the patients received open surgery (69.81%) and radical nephrectomy (67.49%). Most patients (n = 543, 84.06%) had clear cell RCC. Pathological T stage was T1 in 522 cases (80.80%), T2 in 53 (8.2%), T3 in 63 (9.75%), and T4 in 8 (1.24%). The median follow-up was 84 months (IQR, 75–93 months).

The optimal cut-off value of SII is 529 based on the maximum Youden index (Fig. 1). Thus, the patients were divided into two groups. The patients in high SII group (> 529) were significantly associated with older age (P = 0.014), larger tumor (P < 0.001), higher pathological

| Table 1 Clinical characteristics of the patients |
|-----------------------------------------------|
| **Total** | **Before PSM** | **After PSM** |
| SII | < 529 | > 529 | P-value | < 529 | > 529 | P-value |
| No. of patients | 646 | 483 | 163 | | 163 | | |
| Age (years) | 54.77 ± 12.61 | 54.03 ± 12.52 | 56.95 ± 12.68 | 0.014 | 54.93 ± 12.84 | 56.95 ± 12.68 | 0.214 |
| Gender | | | | 1.59 | | | |
| Male | 394 (60.99%) | 287 (59.42%) | 107 (65.64%) | | 105 (64.42%) | 107 (65.64%) | 0.816 |
| Female | 252 (39.01%) | 196 (40.58%) | 56 (34.36%) | | 58 (35.58%) | 56 (34.36%) | |
| Hypertension | 169 (26.16%) | 114 (23.60%) | 55 (33.74%) | 0.011 | 44 (26.99%) | 55 (33.74%) | 0.185 |
| Diabetes mellitus | 77 (11.92%) | 51 (10.56%) | 26 (15.95%) | 0.066 | 18 (11.04%) | 26 (15.95%) | 0.195 |
| Laterality | | | | 0.203 | | | |
| Left | 313 (48.45%) | 227 (47.00%) | 86 (52.76%) | | 80 (49.08%) | 86 (52.76%) | |
| Right | 333 (51.55%) | 256 (53.00%) | 77 (47.24%) | | 83 (50.92%) | 77 (47.24%) | |
| Tumor size (cm) | 4.97 ± 2.53 | 4.57 ± 2.13 | 6.16 ± 3.16 | < 0.001 | 5.85 ± 2.71 | 6.16 ± 3.16 | 0.641 |
| Operative approach | | | | 0.305 | | | |
| Open | 451 (69.81%) | 332 (68.74%) | 119 (73.01%) | | 122 (74.85%) | 119 (73.01%) | |
| Laparoscopic | 195 (30.19%) | 151 (31.26%) | 44 (26.99%) | | 41 (25.15%) | 44 (26.99%) | |
| Nephrectomy | | | | < 0.001 | | | |
| Radical | 436 (67.49%) | 308 (63.77%) | 128 (78.53%) | | 124 (76.07%) | 128 (78.53%) | 0.597 |
| Partial | 210 (32.51%) | 175 (36.23%) | 35 (21.47%) | | 39 (23.93%) | 35 (21.47%) | |
| Pathological T stage | | | | < 0.001 | | | |
| T1 | 522 (80.80%) | 413 (85.51%) | 109 (66.87%) | | 111 (68.10%) | 109 (66.87%) | 0.486 |
| T2 | 53 (8.20%) | 32 (6.63%) | 21 (12.88%) | | 28 (17.18%) | 21 (12.88%) | |
| T3 | 63 (9.75%) | 34 (7.04%) | 29 (17.79%) | | 21 (12.88%) | 29 (17.79%) | |
| T4 | 8 (1.24%) | 4 (0.83%) | 4 (2.45%) | | 3 (1.84%) | 4 (2.45%) | |
| Histologic subtype | | | | 0.807 | | | |
| Clear cell | 543 (84.06%) | 405 (83.85%) | 138 (84.66%) | | 141 (86.50%) | 138 (84.66%) | 0.636 |
| Non-clear cell | 103 (15.94%) | 78 (16.15%) | 25 (15.34%) | | 22 (13.50%) | 25 (15.34%) | |
| Tumor grade | | | | < 0.001 | | | |
| G1 | 24 (3.72%) | 20 (4.14%) | 4 (2.45%) | | 3 (1.84%) | 4 (2.45%) | 0.145 |
| G2 | 340 (52.63%) | 276 (57.14%) | 64 (39.26%) | | 72 (44.17%) | 64 (39.26%) | |
| G3 | 263 (40.71%) | 181 (37.47%) | 82 (50.31%) | | 84 (51.53%) | 82 (50.31%) | |
| G4 | 19 (2.94%) | 12 (2.45%) | 7 (4.56%) | | 3 (1.84%) | 7 (4.56%) | |
| Tumor necrosis | 71 (10.99%) | 38 (7.87%) | 33 (20.25%) | < 0.001 | 32 (19.63%) | 33 (20.25%) | 0.890 |
| Sarcomatoid differentiations | 7 (1.08%) | 3 (0.62%) | 4 (2.45%) | 0.072 | 2 (1.23%) | 4 (2.45%) | 0.685 |
T stage (P < 0.001), higher tumor grade (P < 0.001) and more tumor necrosis (P < 0.001), compared with those in low SII group (< 529). After PSM, 326 patients were identified, and there was no significant difference in baseline between low and high SII group.

Association between preoperative SII and survival outcomes before PSM
After a median follow-up of 84 months, 85 patients (13.16%) had died and 71 deaths (10.99%) were related to RCC. The 5-year OS rates were 93.79% and 76.67% for the patients in low SII and high SII groups, respectively. The 5-year CSS rate was 94.39% for the low SII group, 79.38% for the high SII group. Kaplan–Meier survival curve indicated that higher preoperative SII was associated with lower OS (P = 0.006; Fig. 2a) and CSS (P = 0.012; Fig. 2b). Based on the multivariate analysis, the elevated preoperative SII was an independent predictor of poor prognosis regarding OS (HR = 1.78; 95% CI 1.1–2.87; P = 0.018) and CSS (HR = 1.8; 95% CI 1.07–3.03; P = 0.027; Table 2).

Discussion
In the present study, we explored the prognostic value of preoperative SII in non-metastatic RCC patients who underwent nephrectomy. We observed that high SII is likely to be associated with adverse factors, such as age, tumor size, pathological T stage, tumor grade, and necrosis. Multivariate analyses showed SII was an independent predictor of OS and CSS. Moreover, to limit the influence of bias, we performed PSM and demonstrated that high SII was also an unfavorable factor for OS and CSS in the matched cohort.

The association between inflammation and malignancy has been widely explored in the past decades. Immune cells play an essential role in the inflammatory process leading to the production of cytokines and chemokines that promote tumor development, invasion and metastasis [8]. Therefore, the complex balance between immune cells and substances secreted by inflammation may affect the type of cells detectable in the peripheral circulation. SII, a novel inflammation index, based on the proportion of neutrophil, platelet, and lymphocyte, was found to be associated with the prognosis of several malignancies.

A retrospective multicenter cohort study revealed that high SII (> 900) is associated with poor CSS (HR = 2.32; 95% CI 1.55–3.48) in patients with resectable pancreatic cancer [22]. Chen et al. included 1383 colorectal cancer patients and found high SII (> 340) was an independent predictor of OS and disease-free survival [23]. Zhang et al. conducted a retrospective analysis of 209 patients with BC undergoing radical cystectomy, finding SII was an independent predictor of OS and provided more accurate prognostic prediction than neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein/albumin ratio [17]. Similarly, Jan et al. observed that SII is superior to NLR, PLR and monocyte-to-lymphocyte ratio (MLR) as a predictor of survival in patients with UTUC [24]. Besides, a high SII was associated with adverse characteristics such as lymphovascular invasion, positive lymph node and more aggressive phenotype, which is consistent with our findings.

Similarly, SII was also reported to be associated with survival outcomes in patients with RCC. Chrom et al.
involved metastatic RCC (mRCC) patients treated with the tyrosine kinase inhibitor and found that high SII was an independent factor for inferior OS [25]. Besides, they found that the addition of the SII to the International Metastatic Renal Cell Carcinoma Consortium (IMDC) model in place of neutrophil and platelet counts increased the model's prognostic performance. Lolli et al. also included patients with mRCC treated with sunitinib and observed SII was associated with the OS [18]. To be noted, the improvement of SII value at 6 weeks (from $\geq 730$ to $< 730$) was correlated to a better prognosis, as a possible effect of sunitinib on peripheral blood cells secondary to decline in inflammation process [18]. De Giorgi et al. suggested that SII appears superior to the NLR as a prognostic marker in mRCC patients treated with immune check-point inhibitors [26]. Furthermore, recently, a retrospective study of 176 RCC patients who underwent radical nephrectomy observed that high SII was associated with poor OS ($P = 0.034$) [27]. SII is also associated with an increased TNM stage, which is similar to our results. However, no significant association was found for CSS ($P = 0.29$). Although their study was limited by the small number of patients and the short duration of follow-up, it was valuable for exploring the prognostic value of SII in the non-metastatic RCC. To the best of our knowledge, there are no other studies focusing on the prognostic impact of SII in surgically treated non-metastatic RCC patients. There is no standard cut-off value of SII, and the cut-off value of SII differs from study to study.

Fig. 2 Association between SII and a OS and b CSS in non-metastatic RCC patients after nephrectomy before PSM
Hence, the multicenter study is required to identify standard cut-off value.

The potential mechanism for the prognostic significance of this combination might be explained by the functions of neutrophil, platelet, and lymphocyte. Neutrophils promote angiogenesis and inhibit anti-tumor immune system response, leading to tumor development [9, 12, 28]. Neutrophils also play an important role in the lymphangiogenesis [29]. Furthermore, neutrophils could secret circulating growth factors such as vascular endothelial growth factor, facilitating adhesion and tumor seeding [29, 30]. Huang et al. Observed that neutrophilia is an independent predictor of recurrence in patients with RCC [31]. Besides, the intratumoral neutrophil is associated with poor prognosis in patients with localized and metastatic RCC [32, 33]. Platelet could protect circulating tumor cells (CTCs) during circulation, induce CTC epithelial-mesenchymal transition, and facilitate the extraction of tumor cells, leading to the metastasis of tumor cells [34]. Moschini et al. revealed that the platelet count was associated with survival in patients with bladder carcinoma [35]. Yun et al. also found that decreased mean platelet volume was independently associated with RCC [36]. Lymphocyte plays an important role in anti-tumor immunity. Lymphocyte could induce cytotoxic cell death and inhibit tumor proliferation and migration by secreting cytokines, leading to a host immune response to malignancy [8]. A decreased lymphocyte count might result in the attenuation of immunological anti-tumor response. Lymphopenia was found to be associated with lower survival in patients with advanced bladder cancer and RCC [37, 38]. Besides, higher tumor-infiltrating lymphocytes mean more strongly anti-tumor effect and better survival outcomes [39]. Therefore, the high SII, which reflects thrombocythemia, neutrophilia, or lymphopenia, suggests weak adaptive immune response in patients. All of these could cause more tumor cells to escape from the host immune system, lead to an increase in circulating growth factors and tumor cells, and finally facilitate the tumor invasion and metastasis. Based on the above-mentioned evidence, high SII could serve as an unfavorable factor in cancer patients. However, more large scale studies are required to verify our findings.

SII had significance in clinical practice. SII was calculated based on the neutrophil, platelet, and lymphocyte, which is convenient, easily obtained and commonly tested before the treatment. SII could predict the prognosis of patients, which could be used for risk stratification. It could provide physicians with useful information and guide the treatment, adjuvant therapy and follow-up for patients. However, non-tumor associated inflammation might cause the change of SII. Similarly, the patients with some sort of deficiencies might have more risk of change of SII. Therefore, we need to consider these conditions and might provide supportive treatments. Besides, the individual conditions should be considered during the treatment strategy decision.

Our study is not devoid of limitations. Firstly, the present study is a retrospective study with potential selection bias. To limit the influence of bias, propensity score matching was conducted to balance the baseline. Secondly, the data was extracted from single hospital, and the sample size is moderate. A multicenter study with a large scale is further required. Next, although

| Table 2 Univariate and Multivariate Analyses of Prognostic Factors for OS and CSS in patients with non-metastatic RCC (n = 646) |
|-----------------------------------------------|----------------|----------------|----------------|----------------|
|                                               | OS Multivariate | CSS Multivariate |
|                                               | Univariate     | P-value         | Univariate     | P-value         |
|                                               | HR (95% CI)     | P-value         | HR (95% CI)     | P-value         |
| Age (≥ 55 vs < 55)                            | 2.9 (1.79–4.72) | < 0.001         | 1.77 (1.07–2.92) | 0.025         |
| Gender (male vs female)                       | 1.19 (0.76–1.86) | 0.437         | 1.28 (0.78–2.09) | 0.332         |
| Surgical approach (laparoscopic vs open)      | 0.29 (0.15–0.56) | < 0.001         | 0.41 (0.21–0.81) | 0.009         |
| Type of surgery (partial vs radical)          | 0.17 (0.08–0.37) | < 0.001         | 0.37 (0.17–0.83) | 0.016         |
| Histology (non-clear cell vs clear cell)      | 0.96 (0.53–1.74) | 0.896         | 1.08 (0.58–2.01) | 0.807         |
| T stage (3–4 vs 1–2)                          | 8.9 (5.78–13.7) | < 0.001         | 3.99 (2.5–6.37) | < 0.001         |
| Tumor grade (G3–4 vs G1–2)                    | 4.4 (2.69–7.21) | < 0.001         | 1.83 (1.06–3.14) | 0.03         |
| Tumor necrosis (yes vs no)                    | 5.29 (3.39–8.26) | < 0.001         | 2.38 (1.49–3.79) | < 0.001         |
| Sarcomatoid feature (yes vs no)               | 10.66 (4.3–26.4) | < 0.001         | 2.92 (1.14–7.45) | 0.025         |
| SII (≥ 529 vs < 529)                          | 4.23 (2.76–6.49) | < 0.001         | 2.26 (1.44–3.54) | < 0.001         |
we excluded the patients with the presence of inflammation, other unknown conditions may have existed which affected the neutrophils, lymphocytes, and platelets. Finally, there is no standard cut-off value of SII. Therefore, we determined the cut-off value based on our data. More studies are necessary to identify the optimal cut-off value.

**Conclusion**
In conclusion, preoperative SII is associated with adverse factors for RCC. Furthermore, higher preoperative SII is an independent predictor of poor OS and CSS in surgically treated patients with non-metastatic RCC. More prospective and large scale studies are warranted to validate our findings.
Table 3  Univariate and Multivariate Analyses of Prognostic Factors for OS and CSS in patients with non-metastatic RCC after PSM (n = 326)

|                  | OS Univariate HR (95% CI) | P-value |
|------------------|---------------------------|---------|
|                  | OS Multivariate HR (95% CI) | P-value |
|                  | CSS Univariate HR (95% CI) | P-value |
|                  | CSS Multivariate HR (95% CI) | P-value |
| Age (≥ 55 vs < 55) | 2.06 (1.25–3.4) | 0.004 |
| Gender (male vs female) | 1.16 (0.71–1.89) | 0.550 |
| Surgical approach (laparoscopic vs open) | 0.31 (0.15–0.65) | 0.002 |
| Type of surgery (partial vs radical) | 0.17 (0.06–0.46) | 0.001 |
| Histology (non-clear cell vs clear cell) | 0.71 (0.34–1.48) | 0.365 |
| T stage (3–4 vs 1–2) | 6.4 (4.04–10.14) | < 0.001 |
| Tumor grade (G3–4 vs G1–2) | 4.09 (2.49–6.71) | < 0.001 |
| Tumor necrosis (yes vs no) | 2.91 (1.83–4.65) | < 0.001 |
| Sarcomatoid feature (yes vs no) | 5.53 (2.01–15.2) | < 0.001 |
| SII (> 529 vs < 529) | 1.92 (1.19–3.08) | 0.007 |

Abbreviations
RCC: Renal cell carcinoma; OS: Overall survival; CSS: Cancer-specific survival; HR: Hazard ratio; CI: Confidence interval; SII: Systemic immune-inflammation index; ROC: Receiver operating characteristic.

Acknowledgements
None.

Authors’ contributions
Conception and design: XL and XH; Collection and assembly of data: XH, Y-XS, and Z-QY; Data analysis and interpretation: XL, XH, W-CD and S-CX; Manuscript writing: All authors. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
The data used during the current study are available from the corresponding author on reasonable request.

Ethical approval and consent to participate
All procedures performed in studies involving human participants were according to the ethical standards of the ethics committee of Sichuan University-West China Hospital. The ethics committee of Sichuan University-West China Hospital approved this study, and informed consent was waived by the board.

Competing interests
The authors declare that there is no conflict of interest.

Author details
1 West China School of Medicine/West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China. 2 Department of Urology, West China Hospital, West China Medical School, Sichuan University, 37 Guoxue Street, Chengdu 610041, People’s Republic of China.

Received: 1 April 2020 Accepted: 3 June 2020 Published online: 08 June 2020

References
1. Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C. Global burden of Urologic cancers, 1990–2013. Eur Urol. 2017;71(3):437–46.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2018;68(6):394–424.
3. Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernandez-Pello S, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810.
4. Williamson TJ, Pearson JR, Ichia J, Bolton DM, Lawrentschuk N. Guideline of guidelines: follow-up after nephrectomy for renal cell carcinoma. BJU Int. 2016;117(4):555–62.
5. Jamil MF, Keeley J, Sood A, Dalaia D, Arora S, Peabody JO, et al. Long-term risk of recurrence in surgically treated renal cell carcinoma: a post hoc analysis of the Eastern cooperative oncology group-American college of radiology imaging network E2805 trial cohort. Eur Urol. 2020;77(2):277–81.
6. Unverzagt S, Moldenhauer I, Nothacker M, Rossmeissl D, Hadjinicolaou AV, Peinemann F, et al. Immunotherapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev. 2017;5:CD011673.
7. Meyer E, Pasquier D, Bernardou G, Calais G, Maroun P, Bossi A, et al. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the Getug group. Eur J Cancer. 2018;98:38–47.
8. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.
9. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70.
10. Pyaram K, Yadav VN, Reza MI, Sahu A. Virus-complement interactions: an assiduous struggle for dominance. Futur Virol. 2010;5(6):709–30.
11. Goldberg BS, Ackerman ME. Antibody-mediated complement activation in pathology and protection. Immunol Cell Biol. 2002;80(4):305–17.
12. Coffelt SB, de Visser KE. Cancer: inflammation lights the way to metastasis. Nature. 2014;507(7480):48–9.
13. Huszno J, Kolosza Z, Mrochem-Kwarciak J, Rutkowski T, Sklodowski K. The role of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and platelets in the prognosis of metastatic renal cell carcinoma. Oncology. 2019;97(1):7–17.
14. Guo J, Fang J, Huang X, Liu Y, Yuan Y, Zhang X, et al. Prognostic role of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in prostate cancer: a meta-analysis of results from multivariant analysis. Int J Surg. 2018;60:216–23.
15. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–22.
16. Lotli C, Basso UJ, Derosa L, Scarpi E, Sava T, Santoni M, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget. 2016;7(34):54564–71.
17. Wang K, Diao F, Ye Z, Zhang X, Zhai E, Ren H, et al. Prognostic value of systemic immune-inflammation index in patients with gastric cancer. Chin J Cancer. 2017;36(1):75.

18. Zhang W, Wang R, Ma W, Wu Y, Maskey N, Guo Y, et al. Systemic immune-inflammation index predicts prognosis of bladder cancer patients after radical cystectomy. Ann Transl Med. 2019;7(18):431.

19. Tanega K, Williamson SR. Updates in pathologic staging and histologic grading of renal cell carcinoma. Surg Pathol Clin. 2018;11(4):797–812.

20. Moeh H, Cubilla AL, Humphrey PA, Reuter VE, Ullbricht TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105.

21. Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-weighted weighting under conditions of nonuniform effect. Ann J Epidemiol. 2006;163(3):262–70.

22. Aziz MH, Sideras K, Aziz NA, Mauff K, Haen R, Roos D, et al. The Systemic-immune-inflammatory index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study. Ann Surg. 2019;270(1):139–46.

23. Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. Int J Clin Oncol. 2019;24(13):1997–2005.

24. Jan HC, Yang WH, Ou CH. Combination of the preoperative systemic immune-inflammation index and monocyte-lymphocyte ratio as a Novel prognostic Factor in patients with upper-tract Urothelial carcinoma. Ann Surg Oncol. 2019;26(2):669–84.

25. Chrom P, Zolnierz J, Bodnar L, Stec R, Szczylik C. External validation of the patients with localized renal cell carcinoma. Int Urol Nephrol. 2020.

26. De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, et al. Grade of renal cell carcinoma. Surg Pathol Clin. 2018;11(4):797–812.

27. Öztek E, Bensrolgu H, Özer K, Horsanali MO, Gorgel SN. Systemic immune-inflammation index is a promising non-invasive marker for the prognosis of the patients with localized renal cell carcinoma. Int Urol Nephrol. 2020. https://doi.org/10.1007/s11255-020-02440-y.

28. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99.

29. Tan KW, Chong SZ, Wong FH, Evtard M, Tan SM, Keeble J, et al. Neutrophils contribute to inflammatory lymphangiogenesis by increasing VEGF-A bioavailability and secreting VEGF-D. Blood. 2013;122(22):3666–77.

30. Lopez-Lago MA, Posner S, Thodima VJ, Molina AM, Motzer RJ, Chaganti RS. Neutrophil chemokines secreted by tumor cells mount a lung anti-metastatic response during renal cell carcinoma progression. Oncogene. 2013;32(14):1752–60.

31. Huang J, Dahl DM, Dong L, Liu Q, Cornejo K, Wang Q, et al. Preoperative Neutrophil-to-Lymphocyte ratio and neutrophilia Are independent predictors of recurrence in patients with localized papillary renal cell carcinoma. Biomed Res Int. 2015;2015:891045.

32. Jensen HK, Donskov F, Marcussen N, Nordmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol. 2009;27(28):4709–17.

33. Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol. 2006;24(13):1997–2005.

34. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576–90.

35. Moschini M, Suardi N, Pellucchi F, Rocchini L, La Croce G, Capitanio U, et al. Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma. Anticancer Res. 2014;34(6):3225–30.

36. Yun ZY, Zhang X, Liu ZP, Liu T, Wang RT, Chen H. Association of decreased mean platelet volume with renal cell carcinoma. Int J Clin Oncol. 2017;22(6):1076–80.

37. Joseph N, Dovedi SJ, Thompson C, Lyons J, Kennedy J, Elliott T, et al. Pretreatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer. Ann Oncol. 2016;27(2):294–9.

38. Saroha S, Uzzo RG, P immac E R, Ruth K, Al-Saleem T. Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol. 2013;189(2):454–61.

39. Giraldo NA, Becht E, Vano Y, Petitprez F, Lacroix L, Validire P, et al. Tumor infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin Cancer Res. 2017;23(15):4416–28.